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Background
Adenovirus serotype 5 (Ad5) is a potent vector, but
widespread seroprevalence may limit its potential use.
Replacement of the hexon variable regions (HVR) of
Ad5 with the HVR of the less prevalent Ad48 may result
in a potent vector which bypasses pre-existing vector
immunity.
Methods
Recombinant Ad5 with seven HVRs derived from Ad48
and expressing the VRC EnvA test antigen (rAd5HVR48.
ENVA) was made. 48 healthy volunteers who were sero-
negative to Ad5, Ad48, HIV-1, and HIV-2 were enrolled
in a randomized, double-blind, placebo-controlled, dose-
escalation phase 1 study. The first three groups of
12 subjects received doses of 109, 1010, or 1011 vp of
rAd5HVR48.ENVA vector (n=10/group) or placebo (n=2/
group) at weeks 0, 4, and 24 and the fourth group
received a single injection of 1010 vp or placebo. We per-
formed pre-specified blinded immunogenicity analyses at
day 56 and day 196 after the first immunization.
Results
31/48 (65%) of subjects were female; median age at
enrollment was 24 (range: 18-50). Vaccination was gen-
erally well tolerated: mild to moderate local and sys-
temic reactogenicity was observed after the initial
immunization, more commonly in the highest dose
group, but typically resolved within 24h. No vaccine-
associated SAEs occurred. In all four dose groups, 10
subjects per group developed positive EnvA-specific
ELISA titers and EnvA-specific interferon-gamma
ELISPOT responses following vaccination. Immune
responses were seen two weeks following inoculation in
the majority of subjects. Two subjects per group exhib-
ited no vector- or insert-specific immune responses at
any timepoint and are presumed placebo recipients.
Conclusion
The rAd5HVR48 vector is generally safe and immuno-
genic in humans at all three doses. Immune responses
against EnvA could be detected two weeks following the
first inoculation. Ad5HVR48 is a promising new chimeric
vector to evaluate novel inserts in further clinical trials.
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